GCP Training

Due to the constantly changing regulations, being in compliance with the Good Clinical Practices (GCP) standards is a highly challenging task for the pharmaceutical industry. Pharmaceutical and biotechnology companies are increasingly using trainings to increase the competency of their employees. At HORN Pharmaceutical Consulting we recognize the significance and importance of training and education for all clinical research personnel. Our GCP training courses provide a solid understanding of GCP requirements and an overview of quality assurance for the conduct of clinical trials. 

Our trainings can be offered as tailor-made webinars as well. Just contact us.

No matter whether you need basic or expanded knowledge in regulations for GCPs, our specialists will provide you with the training needed to improve clinical trials and ensure compliance with Good Clinical Practice. Our goal is to provide your employees with an in-depth understanding of the clinical research process, the roles and responsibilities of key players, as well as, regulatory requirements.

In-house Training

The ability to have your specific concerns addressed and discussed is one of the most important factors in any educational program. We offer particularly tailored in-house trainings. Guided by the principle “learning by doing”, we give you the opportunity to exercise what you have learned. In specific workshops, the training participants will be placed in several real life situations such as reviewing pre-study documents and informed consent forms for completeness and compliance; conducting drug accountability; reviewing case report forms for accuracy and adherence to protocol and performing source document verification.


Our specifically tailored GCP-trainings are designed to provide the attendee with thorough knowledge of the following topics:
  • How drugs are discovered and developed for marketing approval
  • What constitutes Good Clinical Practices (GCP)
  • Clinical drug development: trial design and phases
  • The principles of ICH GCP
  • The purpose of a CTA/IMPD as well as IND and its composition
  • How Clinical Trials Applications (CTAs) and Investigational New Drugs (INDs) are filed, reviewed, approved & amended
  • The CTA and IND reporting requirements
  • Specifics for Europe (EU Clinical Trials Directive) and US
  • GCP requirements for Investigational Medicinal Products (IMPD)
  • The different types of study monitoring visits and tasks for each
  • The purpose and composition of the NDA
  • How marketing Authorisations (MAAs) and New Drug Applications (NDAs) are filed, reviewed and approved
  • Sponsor responsibilities after approval
  • How to review study documents and determine compliance
  • How to review case report forms and determine adherence to protocol
  • How to perform source document verification
  • Development of Standard Operating Procedures
  • Quality Assurance audits for clinical trials
  • Quality issues and audit findings in clinical trials
  • How to prepare for authority inspection of clinical trials (FDA, EMA etc.)


    Phone +49 (0) 7251/305 529
    Fax +49 (0) 7251/305 528


    • 18.-19.06.2024
      Online Seminar: Der Regulatory Affairs Manager
    Get all events


    • 19.12.2022
      EU Update regarding Deadlines of Nitrosamine Impurities
    • 01.09.2022
      EU-GMP Annex 1 finally published
    • 26.08.2022
      New Deadlines and Chances for Nitrosamines
    Get all news